By the end of our study ivacaftor/tezacaftor/elexacaftor has been approved for people with CF who have at least one F508del mutation, and it is possible that almost 90% of people with CF will have highly effective CFTR modulators (HEM) available for treatment. The gene discussed is CFTR; the disease is cystic fibrosis.